Advanced Biomed Inc (ADVB) Q3 2024 Earnings Report

Advanced Biomed Inc (ADVB) reported QQ3 2024 results with no revenue disclosed and a net loss of $1.383 million, translating to an EPS of -$0.069. The quarter was characterized by high R&D and G&A spending (R&D $0.250 million; G&A $0.512 million; total operating expenses $0.763 million) against an absence of reported revenue, suggesting the company remains in a development-stage phase focused on advancing its microfluidic biochip platforms for precision oncology. Cash burn was evident in operating cash flow of -$1.066 million and negative free cash flow of -$1.039 million, with a period-end cash balance of $2.664 million. The balance sheet shows modest asset coverage and a healthy-looking current ratio of 1.88, but a very tight cash ratio of 0.038 and a sizable accumulated deficit, underscoring ongoing funding needs.

The company’s pipeline includes APre, AC1000, CTC Enrichment, and ACellScan, along with immunochromogenic kits (ACTCE, ACTCM, AEMT, ACM) and development efforts around ALCGuard for early lung cancer screening. In addition, Advanced Biomed maintains medical clinics in China, potentially providing ancillary near-term revenue opportunities while R&D-driven projects work toward commercialization. Absent disclosed revenue or concrete quarterly guidance, the investment thesis remains highly contingent on successful pipeline validation, regulatory progression, partnerships, and timely financing. Investors should consider the magnitude of the burn, the runway implied by existing liquidity, and the probability of milestones driving any meaningful top-line lift over the next several quarters.